Zhenyu Yue, PhD
- PROFESSOR | Neurology
- PROFESSOR | Neuroscience
Research Topics:
Alzheimer's Disease, Apoptosis/Cell Death, Autophagy, Axonal Growth and Degeneration, Human Genetics and Genetic Disorders, Knockout Mice, Lysosomes/endosome, Molecular Biology, Neuro-degeneration/protection, Parkinson's Disease, Protein Degradation, Protein Kinases, Protein Trafficking & Sorting, Schizophrenia, SynapsesDr. Zhenyu Yue is the Aidekman Research Professor at Department of Neurology and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai. He is the Director of Basic Research of Movement Disorders and the Director for NINDS/NIH Exploratory Program for Parkinson’s disease Research. Dr. Yue’s laboratory investigates cellular and molecular mechanisms for neurological disorders including Parkinson’s disease (PD), Alzheimer’s diseases (AD), Huntington's disease (HD), and schizophrenia/bipolar disorder. His laboratory employs multi-disciplinary approaches, such as systems biology (single-cell RNAseq, proteomics, spatial transcriptomics), molecular biology, protein/lipid biochemistry, optical imaging, immunohistochemistry, iPSC-induced neurons/glia, primary mouse neuron/glia cultures and genetic mouse models. Dr. Yue’s lab is currently focused on microglial functions and senescence in age-related neurodegenerative diseases, gut-brain axis in PD progression and transmission, dopamine neuron vulnerability/resilience in PD/Lew body dementia (LBD), cellular and molecular basis for selective autophagy underlying proteinopathies, synaptic trafficking and PKA-mediated neuronal activity regulation for synaptopathies, including psychiatric diseases. His lab is interested in translational research including biomarker and therapeutic development. Dr. Yue has contributed more than 150 SCI publications including original research articles and reviews/commentaries.
Multi-Disciplinary Training Areas
Neuroscience [NEU], Pharmacology and Therapeutics Discovery [PTD]Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Yue during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- YUNIPEUTICS INC
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- YUNIPEUTICS INC
Royalty Payments:
- Genentech, Inc.; Pfizer Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.